CardioMPO is the only FDA cleared Myeloperoxidase test on the market and is only available from PrognostiX.  PrognostiX is the exclusive licensee of the Cleveland Clinic's patents for MPO used for cardiovascular indications.

PrognostiX, Inc. was founded in 2004 based on novel biomarker technologies developed at the Cleveland Clinic (CC).  The Company is involved in the discovery, development, and commercialization of proprietary molecular biomarkers that aid in the diagnosis and treatment of disease.  The Company headquarters and laboratories are located on the CC campus in Cleveland, Ohio.